Real-world evaluation of compliance and preference in Alzheimer’s disease treatment

References

• QiuCKivipeltoMvon StraussEEpidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward interventionDialogues Clin Neurosci200911211112819585947
   PubMedGoogle Scholar
• PrinceMPrinaMGuerchetMJourney of caring: an analysis of long-term care for dementiaWorld Alzheimer Report 2013London, UKAlzheimer’s Disease International201392
   Google Scholar
• SmallGBullockRDefining optimal treatment with cholinesterase inhibitors in Alzheimer’s diseaseAlzheimers Dement20117217718421056013
   PubMed Web of Science ®Google Scholar
• ZarowitzBJStefanacciRHollenackKO’SheaTGruberJTangalosEGThe application of evidence-based principles of care in older persons (issue 5): Alzheimer’s diseaseJ Am Med Dir Assoc20078318319317349948
   PubMed Web of Science ®Google Scholar
• SmallGDuboisBA review of compliance to treatment in Alzheimer’s disease: potential benefits of a transdermal patchCurr Med Res Opin200723112705271317892635
   PubMed Web of Science ®Google Scholar
• HaberstrohJHampelHPantelJOptimal management of Alzheimer’s disease patients: clinical guidelines and family adviceNeuropsychiatr Dis Treat2010624325320520788
   PubMed Web of Science ®Google Scholar
• CummingsJWinbladBA rivastigmine patch for the treatment of Alzheimer’s disease and Parkinson’s disease dementiaExpert Rev Neurother20077111457146317997695
   PubMedGoogle Scholar
• CummingsJLefèvreGSmallGAppel-DingemanseSPharmacokinetic rationale for the rivastigmine patchNeurology2007694 Suppl 1S10S1317646618
   PubMed Web of Science ®Google Scholar
• KurzAFarlowMLefèvreGPharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a reviewInt J Clin Pract200963579980519392927
   PubMed Web of Science ®Google Scholar
• FarlowMRGrossbergGTSadowskyCHMengXSomogyiMA 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer’s dementiaCNS Neurosci Ther2013191074575223924050
   PubMed Web of Science ®Google Scholar
• WinbladBGrossbergGFrölichLIDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer diseaseNeurology2007694 Suppl 1S14S2217646619
   PubMed Web of Science ®Google Scholar
• CummingsJFroelichLBlackSERandomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs 10 cm2) in Alzheimer’s diseaseDement Geriatr Cogn Disord201233534135322796905
   PubMed Web of Science ®Google Scholar
• WinbladBCummingsJAndreasenNA six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsuleInt J Geriatr Psychiatry200722545646717380489
   PubMed Web of Science ®Google Scholar
• BernabeiRRossiniPMDi CioccioLCompliance and caregiver satisfaction in Alzheimer’s disease: results from the AXEPT StudyDement Geriatr Cogn Dis Extra20122141843223139687
   PubMedGoogle Scholar
• GauthierSRobillardACohenSEMBRACE investigatorsReal-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease: the EMBRACE studyCurr Med Res Opin2013298989100023647369
   PubMed Web of Science ®Google Scholar
• Cruz JentoftAJHernándezBManejo terapéutico con rivastigmina en pacientes con enfermedad de Alzheimer de leve a moderadamente grave en condiciones de práctica clínica habitual. Estudio ENTERPRISE [Rivastigmine as treatment for patients with mild to moderately severe Alzheimer disease under normal clinical practice conditions. The ENTERPRISE study]Neurologia2014291110 Spanish23582372
   PubMed Web of Science ®Google Scholar
• BoadaMArranzFJTransdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer’s disease treated with rivastigmineDement Geriatr Cogn Disord2013351–2233323306147
   PubMed Web of Science ®Google Scholar
• Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human useMed Etika Bioet200291–2121916276663
   PubMedGoogle Scholar
• WinbladBKawataAKBeusterienKMCaregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer’s diseaseInt J Geriatr Psychiatry200722548549117407176
   PubMed Web of Science ®Google Scholar
• AbetzLRofailDMertzanisPAlzheimer’s disease treatment: assessing caregiver preferences for mode of treatment deliveryAdv Ther200926662764419495575
   PubMed Web of Science ®Google Scholar
• EpsteinMInternational Society of PharmacoepidemiologyGuidelines for good pharmacoepidemiology practices (GPP)Pharmacoepidemiol Drug Saf200514858959515918159
   PubMed Web of Science ®Google Scholar
• von ElmEAltmanDGEggerMSTROBE InitiativeThe Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesLancet200737095961453145718064739
   PubMed Web of Science ®Google Scholar
• AndersenKLaunerLJDeweyMEGender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research GroupNeurology19995391992199710599770
   PubMed Web of Science ®Google Scholar
• CankurtaranMYavuzBBCankurtaranESHalilMUlgerZAriogulSRisk factors and type of dementia: vascular or Alzheimer?Arch Gerontol Geriatr2008471253417692938
   PubMed Web of Science ®Google Scholar
• Fernández MartínezMCastro FloresJPérez de Las HerasSMandaluniz LekumberriAGordejuela MenocalMZarranz ImirizalduJJRisk factors for dementia in the epidemiological study of Munguialde County (Basque Country-Spain)BMC Neurol200883918922150
   PubMed Web of Science ®Google Scholar
• ParienteAPinetMMorideYMerlièreYMooreNFourrier-RéglatAFactors associated with persistence of cholinesterase inhibitor treatments in the elderlyPharmacoepidemiol Drug Saf201019768068620583209
   PubMed Web of Science ®Google Scholar
• MassoudFDoraisMCharbonneauCLescrauwaetBBoucherJMLeLorierJDrug utilization review of cholinesterase inhibitors in QuebecCan J Neurol Sci200835450850918973072
   PubMed Web of Science ®Google Scholar
• HerrmannNBinderCDalzielWSmythSCamachoFPersistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database studyDrugs Aging200926540340719552492
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Association and National Alliance for CaregivingFamilies care: Alzheimer’s caregiving in the United States 2004 Available from: www.alz.org/national/documents/report_familiescare.pdfAccessed July 13, 2015
   Google Scholar
• SinghGThomasSKArconaSLingalaVMithalATreatment persistency with rivastigmine and donepezil in a large state medicaid programJ Am Geriatr Soc20055371269127016108961
   PubMed Web of Science ®Google Scholar
• AdlerGMuellerBArticusKThe transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer’s disease under daily practice conditionsInt J Clin Pract201468446547024588972
   PubMed Web of Science ®Google Scholar
• PrinceM10/66 Dementia Research GroupCare arrangements for people with dementia in developing countriesInt J Geriatr Psychiatry200419217017714758582
   PubMed Web of Science ®Google Scholar
• OsterbergLBlaschkeTAdherence to medicationN Engl J Med2005353548749716079372
   PubMed Web of Science ®Google Scholar
• HughesCMMedication non-adherence in the elderly: how big is the problem?Drugs Aging2004211279381115382959
   PubMed Web of Science ®Google Scholar
• VelloneEPirasGTalucciCCohenMZQuality of life for caregivers of people with Alzheimer’s diseaseJ Adv Nurs200861222223118186913
   PubMed Web of Science ®Google Scholar
• MolinuevoJLHernandezBGrupo de Trabajo del Estudio IMPACTPerfil del cuidador informal asociado al manejo clínico del paciente con enfermedad de Alzheimer no respondedor al tratamiento sintomático de la enfermedad [Profile of the informal carer associated with the clinical management of the Alzheimer’s disease patient refractory to symptomatic treatment of the disease]Neurologia2011269518527 Spanish21803459
   PubMed Web of Science ®Google Scholar
• HoweEImproving the quality of life in patients with Alzheimer’s diseasePsychiatry (Edgmont)200858515619727277
   PubMedGoogle Scholar
• Gillette-GuyonnetSAndrieuSCortesFOutcome of Alzheimer’s disease: potential impact of cholinesterase inhibitorsJ Gerontol A Biol Sci Med Sci200661551652016720751
   PubMed Web of Science ®Google Scholar
• WattmoCWallinAKMinthonLProgression of mild Alzheimer’s disease: knowledge and prediction models required for future treatment strategiesAlzheimers Res Ther2013554424099236
   PubMed Web of Science ®Google Scholar
• WattmoCPaulssonEMinthonLLondosEA longitudinal study of risk factors for community-based home help services in Alzheimer’s disease: the influence of cholinesterase inhibitor therapyClin Interv Aging2013832933923682212
   PubMed Web of Science ®Google Scholar
• WattmoCWallinAKLondosEMinthonLRisk factors for nursing home placement in Alzheimer’s disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatmentGerontologist2011511172720562471
   PubMed Web of Science ®Google Scholar
• WattmoCLondosEMinthonLResponse to cholinesterase inhibitors affects lifespan in Alzheimer’s diseaseBMC Neurol20141417325213579
   PubMed Web of Science ®Google Scholar
• OertelWRossJSEggertKAdlerGRationale for transdermal drug administration in Alzheimer diseaseNeurology2007694 Suppl 1S4S917646621
   PubMed Web of Science ®Google Scholar
• ArticusKBaierMTracikFKühnFPreussUWKurzAA 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer’s diseaseInt J Clin Pract201165779079621645184
   PubMed Web of Science ®Google Scholar